Trial · NCT02585778
Outcomes28
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis | From Baseline to Week 24 | ITT population: all randomized participants with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment. | percent change | LEAST_SQUARES_MEAN |
| PRIMARY | Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | From Baseline up to 10 weeks after last study drug administration (maximum of 32 weeks) | Safety population: all randomized participants who received at least one dose or part of a dose of a study drug (treated). | percentage of participants | NUMBER |
| SECONDARY | Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | From Baseline to Week 24 | Modified ITT population (mITT): all randomized and treated participants with one baseline and at least one post-baseline calculated LDL-C value on-treatment. | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis | From Baseline to Week 24 | Participants of the ITT population with one baseline and at least one post-baseline measured LDL-C value on- or off-treatment (Measured LDL-C ITT population). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | From Baseline to Week 24 | Participants of the ITT population with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment at Week 12 (ITT population at Week 12). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Measured LDL-C at Week 12 - ITT Analysis | From Baseline to Week 24 | Participants of the ITT population with one baseline and at least one post-baseline measured LDL-C value on- or off-treatment at Week 12 (Measured LDL-C ITT population at Week 12). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis | From Baseline to Week 24 | Participants of the ITT population with one baseline and at least one post-baseline non-HDL-C value on- or off-treatment (non-HDL-C ITT population). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis | From Baseline to Week 24 | Participants of the ITT population with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis | From Baseline to Week 24 | Participants of the ITT population with one baseline and at least one post-baseline total-C value on- or off-treatment (Total-C ITT population). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis | Up to Week 24 | mITT population. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Reaching Calculated LDL-C <50 mg/dL (1.3 mmol/L) at Week 24 - On-Treatment Analysis | Up to Week 24 | mITT population. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Reaching Calculated Non-HDL-C <100 mg/dL at Week 24 - On-Treatment Analysis | Up to Week 24 | Participants of the mITT population with one baseline and at least one post-baseline Non-HDL-C value on-treatment (Non-HDL-C mITT population). | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Reaching Calculated Non-HDL-C <80 mg/dL at Week 24 - On-Treatment Analysis | Up to Week 24 | Non-HDL-C mITT population. | percentage of participants | NUMBER |
| SECONDARY | Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis | From Baseline to Week 24 | ITT population. | percent change | MEAN |
| SECONDARY | Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | From Baseline to Week 24 | Participants of the ITT population with one baseline and at least one post-baseline HDL-C value on- or off-treatment (HDL-C ITT population). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | From Baseline to Week 24 | ITT population. | percent change | MEAN |
| SECONDARY | Percent Change From Baseline in LDL-C Particle Number at Week 24 - ITT Analysis | From Baseline to Week 24 | Participants of the ITT population with one baseline and at least one post-baseline LDL-C particle number value on- or off-treatment (LDL-C particle number ITT population). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change From Baseline in LDL-C Particle Size at Week 24 - ITT Analysis | From Baseline to Week 24 | Participants of the ITT population with one baseline and at least one post-baseline LDL-C particle size value on- or off-treatment (LDL-C particle size ITT population). | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24 - ITT Analysis | Baseline, Weeks 12 and 24 | ITT population. Here, 'Number Analyzed' = participants with available data at the specified time points for each arm, respectively. | percentage of hemoglobin | MEAN |
| SECONDARY | Absolute Change From Baseline in HbA1c at Weeks 12 and 24 - On-Treatment Analysis | Baseline, Weeks 12 and 24 | mITT population. Here, 'Number Analyzed' = participants with available data at the specified time points for each arm, respectively. | percentage of hemoglobin | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02585778/outcomes